Trending Topic

Stastical analysis indication diabetes mellitus .generative ai
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Saptarshi Bhattacharya, Sanjay Kalra, Lakshmi Nagendra

Very few trials in the history of medical science have altered the treatment landscape as profoundly as the UK Prospective Diabetes Study (UKPDS). Even 44 years after its inception, the trial and post-study follow-up findings continue to fascinate and enlighten the medical community. The study was conceived at a time when there was uncertainty about […]

Steve Bain, EASD 2019: Oral GLP-1 receptor agonist and semaglutide

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 30th 2019

At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Steve Bain discusses the major challenges in developing an oral GLP-1 receptor agonist and how was this overcome with semaglutide.

1. What were the major challenges in developing an oral GLP-1 receptor agonist and how was this overcome with semaglutide? (0:05)
2. Is the oral formulation likely to replace other injectable GLP-1 receptor agonists? (2:12)
3. What have been the key take home messages from the PIONEER clinical trial programme? (3:02)
4. How does oral semaglutide compare with other oral agents such as empagliflozin and sitagliptin? (4:44)
5. Which patients are most likely to benefit from oral semaglutide? (5:37)

Steve Bain has no conflicts of interest to declare in relation to this video.

Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup